The Efficacy of Glucomannan Supplementation in Overweight and Obesity: A Systematic Review and Meta-Analysis of Randomized Clinical Trials

Journal of the American College of Nutrition

Volumn 33, Issue 1, 2014, Pages 70-78

  Onakpoya, Igho ^a,b   Posadzki, Paul ^a   Ernst, Edzard ^a  

^a UNIVERSITY OF EXETER   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

body weight; glucomannan; meta analysis; randomized clinical trial; weight loss

Indexed keywords

DIETARY FIBER; DIETARY SUPPLEMENTS; HUMANS; MANNANS; OBESITY; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 84894033305     PISSN: 07315724     EISSN: 15411087     Source Type: Journal    
DOI: 10.1080/07315724.2014.870013     Document Type: Article

References (38)

1. Barness, L A, Opitz, J M and Gilbert-Barness, E. 2007. Obesity: genetic, molecular, and environmental aspects. Am J Med Genet A, 143: 3016 - 3034.
2. Lyon, M R and Reichert, R G. 2010. The effect of a novel viscous polysaccharide along with lifestyle changes on short-term weight loss and associated risk factors in overweight and obese adults: an observational retrospective clinical program analysis. Altern Med Rev, 15: 68 - 75.
3. Chen, H L, Cheng, H C, Liu, Y, Liu, S and Wu, W. 2006. Konjac acts as a natural laxative by increasing stool bulk and improving colonic ecology in healthy adults. Nutrition, 22: 1112 - 1119.
4. Doi, K. 1995. Effect of konjac fibre (glucomannan) on glucose and lipids. Eur J Clin Nutr, 49: S190 - S197.
5. Cairella, M and Marchini, G. 1995. Evaluation of the action of glucomannan on metabolic parameters and on the sensation of satiation in overweight and obese patients. Clin Ter, 146: 269 - 274.
6. Shima, K, Tanaka, A, Ikegami, H, Tabata, M, Sawazaki, N and Kumahara, Y. 1983. Effect of dietary fiber, glucomannan, on absorption of sulfonylurea in man. Horm Metab Res, 15: 1 - 3.
7. Scalfi, L, Coltorti, A, D'Arrigo, E, Carandente, V, Mazzacano, C, Di Palo, M and Contaldo, F. 1987. Effect of dietary fibre on postprandial thermogenesis. Int J Obes, 11 (Suppl 1): 95 - 99.
8. Gallaher, C M, Munion, J, Hesslink, R Jr, Wise, J and Gallaher, D D. 2000. Cholesterol reduction by glucomannan and chitosan is mediated by changes in cholesterol absorption and bile acid and fat excretion in rats. J Nutr, 130: 2753 - 2759.
9. Vasques, C AR, Rossetto, S, Halmenschlager, G, Linden, R, Heckler, E, Fernandez, M SP and Alonso, JL. 2008. Evaluation of the pharmacotherapeutic efficacy of Garcinia cambogia plus Amorphophallus konjac for the treatment of obesity. Phytother Res, 22: 1135 - 1140.
10. Sood, N, Baker, W L and Coleman, C J. 2008. Effect of glucomannan on plasma lipids and glucose concentrations, body weight, and blood pressure: a systematic review and meta-analysis. Am J Clin Nutr, 88: 1167 - 1175.
11. World Health Organisation. 2011. " Obesity and Overweight Fact Sheet No. 311 ". Accessed at: http://www.who.int/mediacentre/factsheet
12. Schulz, K F, Altman, D G, Moher, D and for the CONSORT Group. 2010. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. PloS Med, 7: e1000251
13. Moher, D, Liberati, A, Tetzlaff, J, Altman, D G and the PRISMA Group. 2009. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA Statement. Ann Intern Med, 151: 264 - 269.
14. 2008. "Review Manager (RevMan)" [computer program]. Version 5.0, Copenhagen, Denmark: The Nordic Cochrane Centre, The Cochrane Collaboration.
15. Deeks, J J, Higgins, J PT and Altman, D G. 2011. " Analysing data and undertaking meta-analyses ". In "Cochrane Handbook for Systematic Reviews of Interventions." Version 5.1.0 (updated March 2011), Edited by: Higgins, J PT and Green, S. The Cochrane Collaboration. (eds.): Chapter 9: Accessed at: http://www.cochrane-handbook.org
16. Sterne, J AC, Egger, M and Moher, D. 2011. " Addressing reporting biases ". In "Cochrane Handbook for Systematic Reviews of Intervention." Version 5.1.0 (updated March 2011), Edited by: Higgins, J PT and Green, S. The Cochrane Collaboration. (eds.): Chapter 10 Accessed at: http://www.cochrane-handbook.org
17. Livieri, C, Novazi, F and Lorini, R. 1992. The use of highly purified glucomannan-based fibers in childhood obesity. Ped Med Chir, 14: 195 - 198.
18. Martino, F, Martino, E, Morrone, F, Carnevali, E, Forcone, R and Niglio, T. 2005. Effect of dietary supplementation on plasma total cholesterol and low density lipoprotein cholesterol in hypercholesterolemic children. Nutr Metab Cardiovasc Dis, 15: 174 - 180.
19. Kraemer, W J, Vingren, J L, Silvestre, R, Spiering, B A, Hatfield, D L, Ho, J Y, Fragala, MS, Maresh, C M and Volek, J S. 2007. Effect of adding exercise to a diet containing glucomannan. Metabolism, 56: 1149 - 1158.
20. Salas-Salvado, J, Farrés, X, Luque, S, Borrell, M, Basora, J, Anguera, A, Torres, F, Bulló, M, Balanza, R and Fiber in Obesity-Study Group. 2008. Effect of two doses of a mixture of soluble fibres on body weight and metabolic variables in overweight or obese patients: a randomised trial. Br J Nutr, 99: 1380 - 1387.
21. Venter, C S, Kruger, H S, Vorster, H H, Serfontein, W J, Ubbink, J B and De Villiers, L S. 1987. The effects of the dietary fibre component konjac-glucomannan on serum cholesterol levels of hypercholesterolemic subjects. Hum Nutr Food Sci Nutr, 41: 55 - 61.
22. Vuskan, V, Jenkins, D JA, Spadafora, P, Swilley, JA, Spadafora, P, Jenkins, DJ, Vidgen, E, Brighenti, F, Josse, RG, Leiter, LA, Xu, Z and Novokmet, R. 1999. Konjac-mannan (glucomannan) improves glycemia and other associated risk factors for coronary heart disease in type 2 diabetes. A randomized controlled metabolic trial. Diabetes Care, 22: 913 - 919.
23. Arvill, A and Bodin, L. 1995. Effect of short-term ingestion of konjac glucomannan on serum cholesterol in healthy men. Am J Clin Nutr, 61: 585 - 589.
24. Biancardi, G, Palmiero, L and Ghirardi, P E. 1989. Glucomannan in the treatment of overweight patients with osteoarthrosis. Curr Ther Res, 46: 908 - 912.
25. Birketvedt, G S, Shimshi, M, Thom, E and Florholmen, J. 2005. Experiences with three different fiber supplements in weight reduction. Med Sci Monit, 11: 5 - 8.
26. Reffo, G C, Ghirardi, P E and Forattini, C. 1990. Double-blind evaluation of glucomannan versus placebo in postinfarcted patients after cardiac rehabilitation. Curr Ther Res Clin Exp, 47: 753 - 758.
27. Vido, L, Facchin, R, Antonello, I, Gobber, D and Rigon, F. 1993. Childhood obesity treatment: double blinded trial on dietary fibres (glucomannan) versus placebo. Padiatr Padol, 28: 133 - 136.
28. Vuskan, V, Sievenpiper, J L Owen, R. 2000. Beneficial effects of viscous dietary fiber from konjac-mannan in subjects with the insulin resistance syndrome. Diabetes Care, 23: 9 - 14.
29. Walsh, D E, Yaghoubian, V and Behforooz, A. 1984. Effect of glucomannan on obese patients: a clinical study. Int J Obes, 8: 289 - 293.
30. Wood, R J, Fernandez, M L, Sharman, M J, Silvestre, R, Greene, C M and Zern, T L. 2007. Effects of a carbohydrate-restricted diet with and without supplemental soluble fibre on plasma low-density lipoprotein cholesterol and other clinical markers of cardiovascular risk. Metabolism, 56: 58 - 67.
31. Yoshida, M, Vanstone, C A, Parsons, W D, Zawistowski, J and Jones, P JH. 2006. Effect of plant sterols and glucomannan on lipids in individuals with and without type II diabetes. Eur J Clin Nutr, 60: 529 - 537.
32. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA). 1798, 2010. Scientific Opinion on the substantiation of health claims related to konjac mannan (glucomannan) and reduction of body weight (ID 854, 1556, 3725), reduction of post-prandial glycaemic responses (ID 1559), maintenance of normal blood glucose concentrations (ID 835, 3724), maintenance of normal (fasting) blood concentrations of triglycerides (ID 3217), maintenance of normal blood cholesterol concentrations (ID 3100, 3217), maintenance of normal bowel function (ID 834, 1557, 3901) and decreasing potentially pathogenic intestinal microorganisms (ID 1558) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA J, 8 [27pp.], doi:10.2903/j.efsa.2010.1798. Accessed at: www.efsa.europa.eu/efsajournal.htm
33. Wittes, J. 2002. Sample size calculations for randomized controlled trials. Epidemiol Rev, 24: 39 - 53.
34. Lachim, J M. 2000. Statistical considerations in the intent-to-treat principle. Control Clin Trials, 21: 167 - 169.
35. Hollis, S and Campbell, F. 1999. What is meant by intention to treat analysis? Survey of published randomised controlled trials. Br Med J, 319: 670 - 674.
36. Ioannidis, J PA, Evans, S JW, Gøstzsche, P C, O'Neill, RT, Altman, DG, Schulz, K, Moher, D and CONSORT Group. 2004. Better reporting of harms in randomized trials. Ann Int Med, 141: 781 - 788.
37. Wadden, T A, Butryn, M L and Wilson, C. 2007. Lifestyle modification for the management of obesity. Gastroentorology, 133: 2226 - 2238.
38. Kaiser, K A, Cofield, S S, Fontaine, K R, Glasser, S P, Thabane, L, Chu, R, Ambrale, S, Dwary, A D, Kumar, A, Nayyar, G, Affuso, O, Beasley, M and Allison, D B. 2011. Is funding source related to study reporting quality in obesity or nutrition randomized control trials in top-tier medical journals?. Int J Obes (Lond), 36: 977 - 981. doi: 10.1038/ijo.2011.207